Brokerages Anticipate ADMA Biologics Inc (ADMA) to Post -$0.51 Earnings Per Share

Brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to announce earnings of ($0.51) per share for the current quarter, according to Zacks. Two analysts have provided estimates for ADMA Biologics’ earnings, with the lowest EPS estimate coming in at ($0.70) and the highest estimate coming in at ($0.32). ADMA Biologics reported earnings of ($0.35) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 45.7%. The business is expected to report its next quarterly earnings results on Friday, February 23rd.

According to Zacks, analysts expect that ADMA Biologics will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.73) to ($1.76). For the next fiscal year, analysts expect that the business will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.25) to ($0.93). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Friday, November 3rd. The biotechnology company reported $0.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $1.10. ADMA Biologics had a negative net margin of 35.00% and a negative return on equity of 76.26%.

Several brokerages have issued reports on ADMA. Maxim Group restated a “buy” rating and set a $8.00 price objective (down from $13.00) on shares of ADMA Biologics in a research report on Monday, December 11th. Raymond James Financial upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, November 14th.

In related news, insider Adam S. Grossman acquired 485,000 shares of the business’s stock in a transaction on Thursday, November 9th. The stock was purchased at an average cost of $2.15 per share, for a total transaction of $1,042,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Eric I. Richman acquired 25,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the completion of the transaction, the director now directly owns 31,300 shares of the company’s stock, valued at $67,295. The disclosure for this purchase can be found here. Insiders have acquired 526,500 shares of company stock valued at $1,131,975 over the last 90 days. Company insiders own 60.44% of the company’s stock.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC increased its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 32.78% of the company’s stock.

Shares of ADMA Biologics (ADMA) opened at $3.67 on Wednesday. ADMA Biologics has a one year low of $2.01 and a one year high of $5.74. The stock has a market cap of $93.89, a PE ratio of -1.84 and a beta of 2.09. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.

Leave a Reply